Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  1. Pubblicazioni

The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression

Articolo
Data di Pubblicazione:
2012
Citazione:
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression / Mocroft, Amanda; Bannister, Wendy P.; Kirk, Ole; Kowalska, Justyna D.; Reiss, Peter; D'arminio monforte, Antonella; Gatell, Jose; Fisher, Martin; Trocha, Hanna; Rakhmanova, Aza; Lundgren, Jens D; Eurosida In, Eurocoord; Castagna, Antonella. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - 17:7(2012), pp. 1291-1300. [10.3851/IMP2407]
Abstract:
Background: The aim of this study was to determine whether there is a protective effect of combination antiretroviral therapy (cART) on the development of clinical events in patients with ongoing severe immunosuppression. Methods: A total of 3,780 patients from the EuroSIDA study under follow-up after 2001 with a current CD4+T-cell count ⠤200 cells/mm3 were stratified into five groups: group 1, viral load (VL)<50 copies/ml on cART; group 2, VL 50-99,999 copies/ml on cART; group 3, VL 50-99,999 copies/ml off cART; group 4, VL⠥100,000 copies/ml on cART; and group 5, VL⠥100,000 copies/ml off cART. Poisson regression was used to identify the risk of (non-fatal or fatal) AIDS- and non-AIDS-related events considered together (AIDS/non-AIDS) or separately as AIDS or non-AIDS events within each group. Results: There were 428 AIDS/non-AIDS events during 3,780 person-years of follow-up. Compared with group 1, those in group 2 had a similar incidence of AIDS/non-AIDS events (incidence rate ratio [IRR] 1.04; 95% CI 0.79-1.36). Groups 3, 4 and 5 had significantly higher incidence rates of AIDS/non-AIDS events compared with group 1; incidence rates increased from group 3 (IRR 1.78; 95% CI 1.25-2.55) to group 5 (IRR 2.36; 95% CI 1.66-3.40), demonstrating the increased incidence of AIDS/non-AIDS events associated with increasing viraemia. After adjustment, the use of cART was associated with a 40% reduction in the incidence of AIDS/non-AIDS events in patients with VL 50-99,999 copies/ml (IRR 0.59; 95% CI 0.41-0.85) and in those with a VL>100,000 copies/ml (IRR 0.66; 95% CI 0.44-1.00). Similar relationships were seen for non-AIDS events and AIDS events when considered separately. Conclusions: In patients with ongoing severe immunosuppression, cART was associated with significant clinical benefits in patients with suboptimal virological control or virological failure. ©2012 International Medical Press.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Acquired Immunodeficiency Syndrome; Adult; CD4 Lymphocyte Count; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Male; Middle Aged; Poisson Distribution; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load; Viremia; Immunocompromised Host; Pharmacology; Pharmacology (medical); Infectious Diseases
Elenco autori:
Mocroft, Amanda; Bannister, Wendy P.; Kirk, Ole; Kowalska, Justyna D.; Reiss, Peter; D'arminio monforte, Antonella; Gatell, Jose; Fisher, Martin; Trocha, Hanna; Rakhmanova, Aza; Lundgren, Jens D; Eurosida In, Eurocoord; Castagna, Antonella
Autori di Ateneo:
CASTAGNA ANTONELLA
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/68206
Pubblicato in:
ANTIVIRAL THERAPY
Journal
  • Dati Generali

Dati Generali

URL

http://www.intmedpress.com/serveFile.cfm?sUID=f6779df7-48ca-492a-a518-e10a030f5c98
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.1.0